Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05565391 · ClinicalTrials.gov registry record
A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 508
- Enrollment target
NCT05565391 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 508 participants.
The verdict
NCT05565391 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 508 participants
- Enrollment target
Study Summary
This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). This study medicine will be compared with standard-of-care (SOC) therapies used in real-world clinical practice. For people receiving elranatamab, we will use data from the phase 2 clinical trial (MagnetisMM-3). We will also use data from two real-world databases, representing the SOC in clinical practice. This study does not seek any participants for enrollment. We will compare the experiences of people receiving elranatamab to people receiving SOC therapies. This way, it will help us to know how well elranatamab can be used for RRMM treatment.
Interventions
- DRUG Elranatamab
- DRUG Standard of care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2022-11-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05565391
The ClinicalTrials.gov registry entry for NCT05565391 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 508 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Elranatamab is the first listed.
NCT05565391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05565391 about?
NCT05565391 is a clinical study titled "A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma". This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). This study medicine will be compared with...
What is the current status of trial NCT05565391?
This trial is currently completed. The enrollment target is 508 participants. The study started on 2022-10-03. Estimated completion is 2022-11-04.
What interventions are being tested in trial NCT05565391?
The interventions under investigation include: Elranatamab (DRUG), Standard of care (DRUG).
Who is sponsoring clinical trial NCT05565391?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.